marijuana stocks news

GW Pharmaceuticals to Report Q1, 2015 Financial Results and Host Conference Call on 4 February, 2015

LONDON, Jan. 27, 2015 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (GWPH) (GWP.L) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will report on 4 February, 2015 its first quarter financial results for the period ending 31 December, 2014. GW will also host a conference call the same day at 8:00 a.m. EST/1:00 p.m. GMT.

Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company’s website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. Sativex is also in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer. GW is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 2/3 clinical development for the treatment of Dravet syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Lennox-Gastaut syndrome. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 clinical development for glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:

GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published.

You May Also Like

Premier Health Group (PHGRF) Expands Technology Development Team and Plans Beta Launch of its Proprietary App in Q2 2019

Premier Health Expands Technology Development Team and Plans Beta Launch of its…

$ENRT Files Form 10-Q

Form 10-Q for ENERTOPIA CORP. 14-Jan-2015 Quarterly Report Item 2. Management’s Discussion…

$FWDG Subsidiary CB Scientific Signs Distribution Agreement with UTest

FutureWorld (FWDG) Subsidiary CB Scientific Signs Distribution Agreement with UTest CB Scientific…

 Choom Holdings Inc. (CHOOF) Completes Acquisition of Phivida Holdings Inc.

Choom Holdings Inc. Completes Acquisition of Phivida Holdings Inc. Choom Holdings Inc.…